Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on developing therapies for cancer and rare diseases, has announced its upcoming participation in the Guggenheim Inaugural Healthcare Innovation Conference. The company's management will engage in a fireside chat on Wednesday, November 13, 2024, at 2:00 pm ET in Boston. The event will be accessible via live webcast through the Events and Presentations section of Protara's website, with a temporary archive available post-presentation.
Protara Therapeutics (Nasdaq: TARA), un'azienda in fase clinica focalizzata sullo sviluppo di terapie per il cancro e le malattie rare, ha annunciato la sua prossima partecipazione alla Guggenheim Inaugural Healthcare Innovation Conference. La direzione dell'azienda parteciperà a una chiacchierata informale mercoledì 13 novembre 2024, alle 14:00 ET a Boston. L'evento sarà accessibile tramite webcasting dal vivo nella sezione Eventi e Presentazioni del sito web di Protara, con un archivio temporaneo disponibile dopo la presentazione.
Protara Therapeutics (Nasdaq: TARA), una empresa en etapa clínica centrada en el desarrollo de terapias para cáncer y enfermedades raras, ha anunciado su próxima participación en la Guggenheim Inaugural Healthcare Innovation Conference. La dirección de la empresa participará en una charla informal el miércoles 13 de noviembre de 2024, a las 2:00 pm ET en Boston. El evento será accesible a través de una transmisión en vivo a través de la sección de Eventos y Presentaciones del sitio web de Protara, con un archivo temporal disponible tras la presentación.
Protara Therapeutics (Nasdaq: TARA)는 암 및 희귀 질환 치료제를 개발하는 임상 단계의 회사로, 구겐하임 제 1회 헬스케어 혁신 회의에 참가할 예정이라고 발표했습니다. 회사 경영진은 2024년 11월 13일 수요일 오후 2시(ET) 보스턴에서 포럼 대담에 참여할 것입니다. 이 행사는 Protara 웹사이트의 이벤트 및 발표 섹션을 통해 실시간 웹캐스트로 접속할 수 있으며, 발표 후에는 임시 아카이브도 제공됩니다.
Protara Therapeutics (Nasdaq: TARA), une entreprise en phase clinique axée sur le développement de thérapies pour le cancer et les maladies rares, a annoncé sa prochaine participation à la Guggenheim Inaugural Healthcare Innovation Conference. La direction de l'entreprise participera à une discussion informelle le mercredi 13 novembre 2024, à 14h00 ET à Boston. L'événement sera accessible par webcast en direct via la section Événements et Présentations du site Web de Protara, avec un archive temporaire disponible après la présentation.
Protara Therapeutics (Nasdaq: TARA), ein Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien für Krebs und seltene Krankheiten konzentriert, hat seine bevorstehende Teilnahme an der Guggenheim Inaugural Healthcare Innovation Conference angekündigt. Das Management des Unternehmens wird am Mittwoch, den 13. November 2024, um 14:00 Uhr ET in Boston an einem informellen Gespräch teilnehmen. Die Veranstaltung wird über einen Live-Stream in der Sektion „Events and Presentations“ der Protara-Website zugänglich sein, mit einem temporären Archiv, das nach der Präsentation verfügbar ist.
- None.
- None.
NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference on Wednesday, November 13, 2024, at 2:00 pm ET in Boston.
A live webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for a limited time following the presentation.
About Protara Therapeutics, Inc.
Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.
Company Contact:
Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836
FAQ
When is Protara Therapeutics (TARA) presenting at the Guggenheim Healthcare Innovation Conference 2024?
How can investors watch Protara Therapeutics' (TARA) Guggenheim Conference presentation?
What type of presentation will Protara Therapeutics (TARA) give at the Guggenheim Conference?
Will Protara Therapeutics' (TARA) Guggenheim Conference presentation be available after the event?
